

Research Article

Coronavirus Infection in Neonates: Neurodevelopmental Outcomes at 18 Months of Age

Mariam Ayed ¹, Zainab Alsaffar,² Zainab Bahzad,² Yasmeen Buhamad,² Ali Abdulkareem,² Alaa AlQattan,² Alia Embaireeg,¹ Mais Kartam,² and Hessa Alkandari^{2,3}

¹Neonatal Department, Maternity Hospital, Kuwait City 900015, Kuwait

²Pediatric Department, Farwaniya Hospital, Kuwait City 81400, Kuwait

³Population Health Department, Dasman Diabetes Institute, Kuwait City, Kuwait

Correspondence should be addressed to Mariam Ayed; mariam.ayed@hsc.edu.kw

Received 16 June 2022; Revised 17 December 2022; Accepted 24 December 2022; Published 2 January 2023

Academic Editor: Arif Siddiqui

Copyright © 2023 Mariam Ayed et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Although most neonates with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection experience only mild disease, its impact on neurodevelopmental outcomes is unknown. This study aimed to assess the 18-month neurodevelopmental outcomes of infants who had SARS-CoV-2 infection as neonates. **Methods.** The authors conducted a prospective cohort study of neonates diagnosed with SARS-CoV-2 infection from June 2020 to December 2020 through nasopharyngeal coronavirus disease 2019 (COVID-19). A total of 58 neonates were identified from the Kuwait National COVID-19 Registry and enrolled. Historical controls were selected from the neonatal follow-up registry and matched in a 2:1 ratio based on sex and gestational age. When the subjects were 18 months of age, their neurodevelopmental outcomes were assessed by two trained assessors using the Bayley Scales of Infant and Toddler Development-3rd Edition (BSID-III). **Results.** Forty children diagnosed with SARS-CoV-2 infection were included in the final analysis. The median age at infection was 18 days (range: 10–26 days). Eighteen (45%) patients were asymptomatic, 15 (37.5%) had a sepsis-like presentation, 5 (12.5%) exhibited respiratory distress, and 2 (5%) had a multisystem inflammatory syndrome in children (MIS-C)-like presentation. At the 18 months follow-up, only one child showed a severe developmental delay and one child had a language delay. BSID-III outcomes did not differ significantly between the SARS-CoV-2-infected and control groups. **Conclusions** There was no difference in neurodevelopmental outcomes at 18 months in children infected with SARS-CoV-2 compared with controls, although longer neurodevelopmental follow-up studies are required.

1. Introduction

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in children has been associated with a multisystem inflammatory syndrome and coronavirus disease 2019 (COVID-19), which are recognized as two distinct clinical entities [1–3]. It is widely known that a smaller proportion of children than adults become ill when infected with SARS-CoV-2 [4].

Neurological symptoms have previously been identified in pediatric cases of COVID-19 [5], with approximately 22% of hospitalized children being affected by neurological manifestations, such as smell/taste disorder, headache, and

stroke [6]. Intracranial hypertension [7] and acute encephalitis [8] have also been reported in children with multisystem inflammatory syndromes.

There are several potential mechanisms by which CNS involvement may occur in association with COVID-19. Animal studies on SARS-CoV-2 have suggested that angiotensin-converting enzyme 2, acting as the viral receptor, may mediate coronavirus-related neuronal damage, and there is also evidence to suggest that the virus can infect the cerebrovascular endothelium and brain parenchyma, particularly in the medial temporal lobe, resulting in apoptosis and necrosis [9]. In addition, postmortem studies of the human brain have yielded evidence indicating that

human coronavirus variants and SARS-CoV can infect both neurons and glia, and increased cytokine serum levels associated with SARS-CoV infection may indicate increased cytokine production [9]. Antineuronal and antiglial autoantibodies have been detected in the cerebrospinal fluid of patients with COVID-19 and neurological symptoms, which raises the possibility that autoimmune mechanisms are involved in the pathogenesis of COVID-19 with neurological involvement [10].

Although most neonates with SARS-CoV-2 infection have mild disease, the impact on long-term neurodevelopmental outcomes is currently unknown. It has been shown that birth during the COVID-19 pandemic, but not in utero exposure to maternal SARS-CoV-2, is associated with differences in neurodevelopmental outcomes at 6 months of age [11]. Another study showed that newborns exposed in utero to SARS-CoV-2 exhibit largely normal neurological development in the first few months of life [12]. However, these studies provided only a short-term perspective on neurodevelopmental outcomes.

The objective of this study was thus to assess the neurodevelopmental outcomes at 18 months in infants who had confirmed SARS-CoV-2 infection as neonates. It has been hypothesized that neonatal SARS-CoV-2 infection may lead to adverse neurodevelopmental outcomes.

2. Materials and Methods

2.1. Patient Enrollment. We conducted a prospective cohort study of neonates diagnosed with SARS-CoV-2 infection between June 2020 and December 2020. Neonates underwent nasopharyngeal COVID-19 PCR according to our national COVID-19 protocol. Neonates were confirmed for testing if they fulfilled one of the following criteria: (1) contact with a known COVID-19 patient; (2) symptoms of fever, cough, or respiratory distress; or (3) tested as a screening test prior to hospital admission (per our national guideline to screen all patients before hospitalization). Verbal informed consent was obtained from the children's parents before conducting the study. Ethics approval was granted by the Ministry of Health of Kuwait (approval numbers: 2021–1638).

A total of 58 neonates were identified from the Kuwait National COVID-19 Registry and enrolled in the prospective SARS-CoV-2 infection outcome cohort. Of these, 6 were lost to follow-up, 2 refused to participate in the neurodevelopmental outcome study, 6 left the country, and 1 died from COVID-19 complications. Four neonates were excluded as we were unable to determine their COVID-19 status due to equivocal results; all neonates were asymptomatic and were tested due to positive contact with COVID-19 patients; therefore, repeat testing was not done. Historical controls were selected from the neonatal follow-up registry and matched in a 2:1 ratio based on sex and gestational age.

Data were retrieved from hospital records and included demographic details, parental education, maternal age at the birth of the child, clinical features, hospital course, and morbidity assessment, including any seizure episode or rehospitalization.

2.2. Definitions. Respiratory distress was defined as the presence of either increased work of breathing or oximetry of $<93\%$. We used the multisystem inflammatory syndrome (MIS-C) definition of the CDC and AAP [13, 14]. MIS-C often occurs in patients aged <21 years, with the following clinical criteria: a minimum 24-hour history of subjective or objective pyrexia $\geq 38.0^{\circ}\text{C}$, severe illness requiring hospitalization, and involvement of two or more organ systems (i.e., cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological). Laboratory evidence of inflammation was defined as one or more of the following: elevated C-reactive protein (CRP), erythrocyte sedimentation rate, fibrinogen, procalcitonin, D-dimer, ferritin, lactate dehydrogenase, or interleukin-6; elevated neutrophils or reduced lymphocytes; and low albumin.

A diagnosis of central nervous system comorbidities and chromosomal abnormalities was ruled out in the enrolled neonates.

2.3. Assessment of Neurodevelopmental Outcomes. When the subjects were 18 months of age, their neurodevelopmental outcomes were assessed by two trained assessors using the Bayley Scales of Infant and Toddler Development-3rd Edition (BSID-III) [15]. These scales are age-standardized, with composite cognitive, motor, and language scales with a normative mean of 100 and a standard deviation (SD) of 15. A diagnosis of moderate developmental delay was given for the worst composite score of 70–84 in one or more of the three domains. However, the severe developmental delay was used for a score of <70 for any of the three domains or when a score could not be assigned due to severe mental deficiency or cerebral palsy, as appraised using the gross motor function classification system (GMFCS) [16]. Additionally, both blindness and deafness were evaluated by a pediatrician. Blindness was defined as a visual acuity of less than 6/60 in the better eye, and deafness was defined as a hearing impairment requiring amplification, cochlear implant, or worse [17]. We also obtained anthropometric variables, including head circumference, length, and weight, measured using standard techniques and growth standards of the World Health Organization.

2.4. Statistical Analysis. Categorical data are presented as proportions and continuous data as the median and interquartile range (IQR). Differences in clinical data between infants were compared using Pearson's chi-square test for categorical variables (Fisher's exact test was used when a frequency was less than 5) and with the Wilcoxon rank-sum test for continuous variables. The statistical significance was set at $P < 0.05$. All statistical analyses were performed using Stata/IC 14.2 (StataCorp, College Station, Texas, 2015).

3. Results

Forty children were diagnosed with SARS-CoV-2 infection and included in the final analysis. The demographic details of the study cohort are presented in Table 1. The median age at infection was 18 days (IQR: 10–26 days). Two of the infected

TABLE 1: Demographic characteristics of the study subjects.

Variable	SARS-CoV-2 exposed, <i>N</i> = 40	Historical control, <i>N</i> = 80	<i>P</i> value
Gestational age, week	38 (37–40)	39.2 (38–40)	0.716
Sex			
Male	19 (47.5%)	39 (48.8%)	0.872
Female	21 (52.5%)	41 (51.2%)	
Birth weight, grams	3000 (2500–3420)	3457 (3147–3765)	0.12
Mode of delivery			
Caesarean section	13 (57.5%)	42 (52.5%)	0.532
Vaginal birth	17 (42.5%)	38 (47.5%)	
5 minutes Apgar score	8 (7–10)	8 (7–9)	0.128
Maternal education			
Educated	1 (2.5%)	5 (6.2%)	
Elementary education	2 (5%)	2 (4.5%)	0.104
High school	4 (10%)	7 (68.7%)	
Diploma	13 (32.5%)	29 (36%)	
Bachelor/PhD	20 (50%)	37 (46.2%)	
Maternal age, years	27.3 (25–32)	27.7 (26–31.7)	0.296
Paternal education			
Educated	1 (2.5%)	0	
Elementary education	5 (12.5%)	10 (12.5%)	0.109
High school	4 (10%)	12 (15%)	
Diploma	12 (30%)	28 (35%)	
Bachelor/PhD	18 (45%)	30 (37.5%)	
Age at follow-up, months	18.6 (18.2–19.5)	18.7 (18.4–19.3)	0.174

Data are expressed as number (%) and median (interquartile range).

neonates were born to mothers who were SARS-CoV-2 infected at the time of birth. Eighteen (45%) patients were asymptomatic; 17 were tested due to contact with known COVID-19 patients, and 1 was tested before inguinal hernia surgical repair. Fifteen (37.5%) had sepsis-like presentations (fever, lethargy, and poor feeding), five (12.5%) had respiratory distress, and two (5%) had MIS-C-like presentations. Of the 5 patients with respiratory distress, 4 received supplemental oxygen, and 1 received a humidified high-flow nasal cannula. Only one patient with the MIS-C-like presentation required invasive respiratory and circulatory support. None of the infants with MIS-C had cardiac arrhythmia or dilated coronaries. None of the symptomatic infants had a concomitant positive viral or bacterial screening. The median duration of hospital stay was 4 days (IQR: 2–14 days).

During the 18-month follow-up period, two infants required rehospitalization: one with a simple febrile seizure at 7 months of age and the second with acute bronchiolitis at 4 months of age.

The maternal and infant characteristics did not significantly differ between the exposed and unexposed groups (Table 2).

At 18 months, there were no differences in the Bayley-III composite scores between the exposed and control groups. In the SARS-CoV-2-exposed group, one infant had a score of less than 70 in the motor, cognitive, and language composite scores, and one infant had a language composite score of less than 85. The infant with a score <70 in all domains had a neonatal MIS-C-like presentation. She presented with lethargy, fever, tachycardia, and hypotension at the age of 8 days and required invasive ventilation, inotropic support,

and intravenous immunoglobulin therapy. She developed seizures on day 10 and had markedly increased C-reactive protein (CRP), myocardial enzyme, and D-dimer levels. A lumbar puncture was not performed because of instability. Her septic workup, including blood and endotracheal cultures, was negative. Magnetic resonance imaging (MRI) revealed right temporal and bilateral basal ganglia hemorrhagic foci with abnormal cortical and subcortical signal intensity on T2-weighted images in both the frontoparietal and posterior parietal regions. The second child, who scored less than 85 in the language composite score, presented with fever and pneumonia, which were confirmed by chest radiographic imaging at 14 days of age. He received supportive treatment for 5 days, including a humidified high-flow nasal cannula for 3 days. He had normal hearing and a normal neurological examination.

4. Discussion

This prospective cohort study compared the neurodevelopmental outcomes at 18 months of age in 40 children diagnosed with SARS-CoV-2 infection with a group of 80 historical controls matched in terms of maternal and infant characteristics at baseline. The study found no significant difference in Bayley-III composite scores between the two groups, indicating similar neurodevelopmental outcomes.

Overall, the prognosis of neonates with SARS-CoV-2 infection was good, with only one infant having a severe developmental delay and one having a language delay. Almost half of our patients were asymptomatic, and one with an MIS-C-like presentation developed seizures and a brain injury on MRI. There has been significant interest in the

TABLE 2: Follow-up outcomes at 18 months.

Variables	SARS-CoV-2-infected group, N = 40	Control group, N = 80	P value
Bayley-III			
Motor composite score	100 (91–107)	97 (88–107)	0.101
71–85	0	2 (2.5%)	0.786
<70	1 (2.5%)	1 (1.2%)	
Fine motor	11 (10–12)	10 (9–12)	0.21
Gross motor	9 (7–10)	9 (6–10)	0.231
Cognitive composite score	105 (100–115)	110 (100–115)	0.952
71–85	0	3 (3.7%)	0.261
<70	1 (2.5%)	0	
Language composite score	100 (89–109)	100 (89–109)	0.785
Expressive	9 (7–12)	9 (8–11)	0.971
Receptive	10 (8–12)	10 (8–12)	0.645
71–85	1 (2.5%)	3 (3.7%)	0.864
<70	1 (2.5%)	1 (1.2%)	
Cerebral palsy	1 (2.5%)	2 (2.5%)	0.131
Seizure	1 (2.5%)	0	1
Deafness	0	1 (1.2%)	0.293
Blindness	0	0	
Weight (kg)	11.1 (10.2–12.7)	11.7 (10.7–12.9)	0.212
Length (cm)	82 (79–84)	83 (78–86)	0.304
Head circumference (cm)	47.6 (46.9–48.8)	48.5 (47.5–49)	0.138

Data are expressed as number (%) or median, interquartile range (IQR).

manifestations of SARS-CoV-2 infection in the pediatric population, particularly neurological manifestations [19, 18]. The systemic inflammatory response commonly observed in adults is much rarer in the pediatric population [19]. However, long COVID may well be an under-recognized phenomenon [20]. The challenge of recognizing the clinical characteristics of COVID-19 among other neonatal diseases is apparent [21]; some recognized manifestations of SARS-CoV-2 infection in children include stroke [22], seizures, seizure-like activities [23–25], headaches [23], dizziness [23], meningoencephalitis [23, 26–28], and opsoclonus [29]. Rare neurological complications include intracranial hemorrhage, cranial neuropathies, Guillain-Barré syndrome, and visual impairments [30]. Many neurological manifestations have been observed in association with MIS-C [31]. The underlying pathophysiology driving these clinical manifestations of SARS-CoV-2 infection remains to be fully elucidated, although immune dysregulation and autoreactivity have been shown to correlate with disease severity in children [32], and the use of blood biomarkers for the diagnosis of brain injury in patients with COVID-19 has been proposed [33]. Neuroimaging performed in children with SARS-CoV-2 infection most commonly reveals postinfectious immune-mediated acute disseminated encephalomyelitis-like changes in the brain, myelitis, and neural enhancement [34]. Focal cerebral arteriopathy [35] has also been identified. Diffusion restriction [36] and cerebral white matter injury [37] have also been described in the neonatal population.

The neurodevelopmental outcomes of neonates infected with SARS-CoV-2 are of particular interest, given the potential implications for the child's long-term prognosis and

functional outcomes. The effect of SARS-CoV-2 infection, specifically in neonates, has been relatively understudied [38, 39]. There is evidence that most infected neonates are asymptomatic or experience only mild disease [38, 40], although risks of direct and indirect adverse health outcomes have been identified [39, 41]. In this study, only one infant had a severe developmental delay and one had a language delay at 18 months. It is difficult at this stage to establish a direct link between SARS-CoV-2 infection and adverse neurodevelopmental outcomes. However, we can speculate that, like with any other viral infection, systemic inflammation induced by cytokines can lead to neuronal injury [42]. Even without meningitis, the infection can lead to brain injury and neurodevelopmental impairment [42].

Few studies have investigated neurodevelopmental outcomes in neonates exposed to SARS-CoV-2 infection [43]. However, one study showed that in utero exposure to maternal SARS-CoV-2 infection is not associated with adverse neurodevelopmental outcomes at 6 months of age [11]. Another study showed that newborns exposed to SARS-CoV-2 in utero have largely normal neurological development in the first few months of life. A multicenter observational study is also underway with the aim of reviewing neurodevelopmental outcomes at 6 months [44]. However, long-term follow-up is required to provide a more accurate picture. Telehealth may be a useful method for monitoring the long-term neurodevelopmental outcomes of neonates who develop SARS-CoV-2 infection [45].

This study has several limitations. First, the control population was a historical cohort; therefore, their data may be incomplete. Second, the sample size is relatively small. Third, we were unable to control for unmeasured

confounders in this study. The disease severity could confound the relationship between adverse neurodevelopmental outcomes and COVID-19 disease in our infants. We also excluded infants with equivocal PCR testing; this exclusion could lead to selection bias.

5. Conclusion

This study demonstrated no difference in neurodevelopmental outcomes in children infected with SARS-CoV-2 compared with a historical control group. However, additional long-term follow-up is required to ensure this remains true after 18 months. Furthermore, neurodevelopmental outcomes are likely to be largely normal, as most neonates are asymptomatic or have mild symptoms. Neonates with severe COVID-19 or neurological involvement are likely at a higher risk of neurodevelopmental impairment.

Abbreviations

BSID-III:	Bayley Scales of Infant and Toddler Development-3rd Edition
COVID-19:	Coronavirus disease 2019
GMFCS:	Gross motor function classification system
IQR:	Interquartile range
MIS-C:	Multisystem inflammatory syndrome in children
SARS-CoV-2:	Severe acute respiratory syndrome coronavirus-2
SD:	Standard deviation.

Data Availability

The analysis code compiled using Stata software is available from the corresponding author. Data sharing with readers is not available because of the requirements of the Ethics Committee of the Ministry of Health of Kuwait.

Ethical Approval

Ethics approval was granted by the Ministry of Health of Kuwait (registration number 2021-1638) in accordance with the principles proclaimed by the United Nations regarding the obligations of States Parties to ensure the survival and development of the child to the maximum extent possible [47].

Consent

Verbal informed consent was obtained from the children's parents prior to conducting the study.

Disclosure

A preprint has previously been published in medrxiv (<https://www.medrxiv.org/content/10.1101/2022.04.15.22273460v1.full.pdf>) [46].

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors' Contributions

MA and HA conceptualized and planned the study, drafted the proposal and manuscript, and planned and oversaw data collection. MA also did the statistical analysis. ZA, ZB, AA, and MK collected data and helped in drafting the manuscript. All authors have agreed to submit this final version of the paper to the journal.

Acknowledgments

The authors would like to thank the respective register holders and the Pediatric COVID-19 Kuwait National Registry. The authors acknowledge the editorial support, in the form of medical edits, assembling tables, and referencing, provided by Editage, Cactus Communications, and San Francisco Edit.

References

- [1] C. Diorio, S. E. Henrickson, L. A. Vella et al., "Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2," *Journal of Clinical Investigation*, vol. 130, no. 11, pp. 5967-5975, 2020.
- [2] K. L. LaRovere, B. J. Riggs, T. Y. Poussaint et al., "Neurologic involvement in children and adolescents hospitalized in the United States for COVID-19 or multisystem inflammatory syndrome," *JAMA Neurology*, vol. 78, no. 5, pp. 536-547, 2021.
- [3] B. Jonat, M. Gorelik, A. Boneparth et al., "Multisystem inflammatory syndrome in children associated with coronavirus disease 2019 in a children's hospital in New York City: patient characteristics and an institutional protocol for evaluation, management, and follow-up," *Pediatric Critical Care Medicine*, vol. 22, no. 3, pp. e178-e191, 2021.
- [4] A. Christy, "COVID-19: a review for the pediatric neurologist," *Journal of Child Neurology*, vol. 35, no. 13, pp. 934-939, 2020.
- [5] O. Abdel-Mannan, M. Eyre, U. Löbel et al., "Neurologic and radiographic findings associated with COVID-19 infection in children," *JAMA Neurology*, vol. 77, no. 11, pp. 1440-1445, 2020.
- [6] A. M. Alcamo, J. L. McGuire, H. K. Kanthimathinathan, J. D. Roa, and E. L. Fink, "Worldwide epidemiology of neuro-coronavirus disease in children: lessons for the next pandemic," *Current Opinion in Pediatrics*, vol. 33, no. 6, pp. 580-590, 2021.
- [7] A. Baccarella, A. Linder, R. Spencer et al., "Increased intracranial pressure in the setting of multisystem inflammatory syndrome in children, associated with COVID-19," *Pediatric Neurology*, vol. 115, pp. 48-49, 2021.
- [8] S. Olivotto, E. Basso, R. Lavatelli et al., "Acute encephalitis in pediatric multisystem inflammatory syndrome associated with COVID-19," *European Journal of Paediatric Neurology*, vol. 34, pp. 84-90, 2021.
- [9] G. Aghagoli, B. Gallo Marin, N. J. Katchur, F. Chaves-Sell, W. F. Asaad, and S. A. Murphy, "Neurological involvement in COVID-19 and potential mechanisms: a review," *Neurocritical Care*, vol. 34, no. 3, pp. 1062-1071, 2021.

- [10] C. Franke, C. Ferse, J. Kreye et al., "High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms," *Brain, Behavior, and Immunity*, vol. 93, pp. 415–419, 2021.
- [11] L. C. Shuffrey, M. R. Firestein, M. H. Kyle et al., "Association of birth during the COVID-19 pandemic with neurodevelopmental status at 6 months in infants with and without in utero exposure to maternal SARS-CoV-2 infection," *JAMA Pediatrics*, vol. 176, Article ID e215563, 2022.
- [12] D. Buonsenso, S. Costa, L. Giordano et al., "Short- and mid-term multidisciplinary outcomes of newborns exposed to SARS-CoV-2 in utero or during the perinatal period: preliminary findings," *European Journal of Pediatrics*, vol. 181, no. 4, pp. 1507–1520, 2022.
- [13] CDC, "CDC information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C)," 2021, <https://emergency.cdc.gov/han/2020/han00432.asp>.
- [14] "AAP multisystem inflammatory syndrome in children (MIS-C) interim guidance," <https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/multisystem-inflammatory-syndrome-in-children-mis-c-interim-guidance/>.
- [15] D. Michalec, "Bayley scales of infant development: third edition," in *Encyclopedia of Child Behavior and Development*, S. Goldstein and J. A. Naglieri, Eds., Springer, Salt Lake City, Utah, 2011.
- [16] R. Palisano, P. Rosenbaum, S. Walter, D. Russell, E. Wood, and B. Galuppi, "Development and reliability of a system to classify gross motor function in children with cerebral palsy," *Developmental Medicine and Child Neurology*, vol. 39, no. 4, pp. 214–223, 2008.
- [17] T. Y. C. Ching, H. Dillon, L. Button et al., "Age at intervention for permanent hearing loss and 5-year language outcomes," *Pediatrics*, vol. 140, no. 3, Article ID e20164274, Sep 2017.
- [18] Y. Kim, S. A. Walser, S. J. Asghar, R. Jain, G. Mainali, and A. Kumar, "A comprehensive review of neurologic manifestations of COVID-19 and management of pre-existing neurologic disorders in children," *Journal of Child Neurology*, vol. 36, no. 4, pp. 324–330, 2021.
- [19] H. Wu, H. Zhu, C. Yuan et al., "Clinical and Immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in Wuhan, China," *JAMA Network Open*, vol. 3, no. 6, Article ID e2010895, 2020.
- [20] C. L. H. Brackel, C. R. Lap, E. P. Buddingh et al., "Pediatric long-COVID: an overlooked phenomenon?" *Pediatric Pulmonology*, vol. 56, no. 8, pp. 2495–2502, 2021.
- [21] W. B. d Carvalho, M. A. C. Gibelli, V. L. J. Krebs, V. M. L. T. Calil, C. M. Nicolau, and C. Johnston, "Neonatal SARS-CoV-2 infection," *Clinics*, vol. 75, Article ID e1996, 2020.
- [22] L. A. Beslow, A. B. Linds, C. K. Fox et al., "Pediatric ischemic stroke: an infrequent complication of SARS-CoV-2," *Annals of Neurology*, vol. 89, no. 4, pp. 657–665, 2021.
- [23] B. Dilber, Z. G. G. Aydın, O. Yeşilbaş et al., "Neurological manifestations of pediatric acute COVID infections: a single center experience," *Journal of Tropical Pediatrics*, vol. 67, no. 3, Article ID fmab062, 2021.
- [24] R. Dugue, K. C. Cay-Martínez, K. T. Thakur et al., "Neurologic manifestations in an infant with COVID-19," *Neurology*, vol. 94, no. 24, pp. 1100–1102, 2020.
- [25] S. Ninan, P. Thompson, T. Gershon et al., "Fatal pediatric COVID-19 case with seizures and fulminant cerebral edema," *Child Neurology Open*, vol. 8, 2021.
- [26] M. Gaughan, S. Connolly, S. O'Riordan, N. Tubridy, C. McGuigan, and J. A. Kinsella, "Pediatric parainfectious encephalitis associated with COVID-19," *Neurology*, vol. 96, no. 11, pp. 541–544, 2021.
- [27] M. Hilado, M. Banh, J. Homans, and A. Partikian, "Pediatric autoimmune encephalitis following COVID-19 infection," *Journal of Child Neurology*, vol. 37, no. 4, pp. 268–272, 2022.
- [28] N. Lorenz, A. Treptow, S. Schmidt et al., "Neonatal early-onset infection with SARS-CoV-2 in a newborn presenting with encephalitic symptoms," *The Pediatric Infectious Disease Journal*, vol. 39, no. 8, p. e212, 2020.
- [29] D. L. Heald, I. M. Devine, R. L. Smith, S. A. Holsopple, J. L. Arasmith, and R. W. Arnold, "Opsoclonus after COVID-19 in an infant," *Pediatric Neurology*, vol. 117, p. 34, 2021.
- [30] P. K. Panda, I. K. Sharawat, P. Panda, V. Natarajan, R. Bhakat, and L. Dawman, "Neurological complications of SARS-CoV-2 infection in children: a systematic review and meta-analysis," *Journal of Tropical Pediatrics*, vol. 67, no. 3, Article ID fmaa070, 2021.
- [31] T. Govil-Dalela and L. Sivaswamy, "Neurological effects of COVID-19 in children," *Pediatric Clinics of North America*, vol. 68, no. 5, pp. 1081–1091, 2021.
- [32] A. Ramaswamy, N. N. Brodsky, T. S. Sumida et al., "Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children," *Immunity*, vol. 54, no. 5, pp. 1083–1095.e7, 2021.
- [33] S. T. DeKosky, P. M. Kochanek, A. B. Valadka et al., "Blood biomarkers for detection of brain injury in COVID-19 patients," *Journal of Neurotrauma*, vol. 38, pp. 1–43, 2021.
- [34] C. E. Lindan, K. Mankad, D. Ram et al., "Neuroimaging manifestations in children with SARS-CoV-2 infection: a multinational, multicentre collaborative study," *The Lancet Child & Adolescent Health*, vol. 5, no. 3, pp. 167–177, 2021.
- [35] S. M. M. Mirzaee, F. G. Gonçalves, M. Mohammadifard, S. M. Tavakoli, and A. Vossough, "Focal cerebral arteriopathy in a pediatric patient with COVID-19," *Radiology*, vol. 297, no. 2, pp. E274–E275, 2020.
- [36] P. J. Martin, M. Felker, and R. Radhakrishnan, "MR imaging findings in a neonate with COVID-19-associated encephalitis," *Pediatric Neurology*, vol. 119, pp. 48–49, 2021.
- [37] H. Yildiz, E. Yarci, S. E. Bozdemir et al., "COVID-19-associated cerebral white matter injury in a newborn infant with afebrile seizure," *The Pediatric Infectious Disease Journal*, vol. 40, no. 7, pp. e268–e269, 2021.
- [38] C. E. Stafstrom and L. L. Jantzie, "COVID-19: neurological considerations in neonates and children," *Children*, vol. 7, no. 9, p. 133, 2020.
- [39] L. Ryan, F. B. Plötz, A. van den Hoogen et al., "Neonates and COVID-19: state of the art: neonatal Sepsis series," *Pediatric Research*, vol. 91, no. 2, pp. 432–439, 2022.
- [40] C. Pietrasanta, A. Ronchi, F. Schena et al., "SARS-CoV-2 infection and neonates: a review of evidence and unresolved questions," *Pediatric Allergy & Immunology*, vol. 31, no. S26, pp. 79–81, 2020.
- [41] F. Götzinger, B. Santiago-Garcia, V. Fumadó-Pérez, F. Brinkmann, and M. Tebruegge, "The ability of the neonatal immune response to handle SARS-CoV-2 infection," *The Lancet Child & Adolescent Health*, vol. 5, no. 3, pp. e6–e7, 2021.
- [42] J. J. Volpe, T. E. Inder, B. T. Darras et al., *Volpe's Neurology of the Newborn*, Elsevier, 2017.

- [43] T. G. Singer, K. D. Evankovich, K. Fisher, G. J. Demmler-Harrison, and S. R. Risen, "Coronavirus infections in the nervous system of children: a scoping review making the case for long-term neurodevelopmental surveillance," *Pediatric Neurology*, vol. 117, pp. 47–63, 2021.
- [44] T. Xiao, S. Xia, L. Zeng et al., "A multicentre observational study on neonates exposed to SARS-CoV-2 in China: the Neo-SARS-CoV-2 Study protocol," *BMJ Open*, vol. 10, no. 7, Article ID e038004, 2020.
- [45] N. L. Maitre, K. L. Benninger, M. L. Neel et al., "Standardized neurodevelopmental surveillance of high-risk infants using telehealth: implementation study during COVID-19," *Pediatric Quality & Safety*, vol. 6, no. 4, p. e439, 2021.
- [46] M. Ayed, Z. Alsaffar, Z. Bahzad et al., "Coronavirus infection in neonates: neurodevelopmental outcomes at 18 months of age," <https://www.medrxiv.org/content/10.1101/2022.04.15.22273460v1>.
- [47] "UN committee on the rights of the child," 1995, <https://www.ohchr.org/en/instruments-mechanisms/instruments/convention-rights-child>.